UBS has maintained a 'Buy' rating for Microsoft, setting a target price of $510. Analyst Karl Keirstead highlighted the company's partnership with OpenAI, noting that while investments may dilute earnings per share and pressure capital, the growth of the Azure cloud platform will outweigh these concerns.
14:50 21.10.2024
UBS maintains a 'Buy' rating for Microsoft, setting a target price of $510. Analyst Karl Keirstead highlights the company's partnership with OpenAI, noting that while investments may dilute earnings per share and pressure capital requirements, growth in the Azure cloud platform is expected to outweigh these challenges. As of October 21, 2024, Microsoft shares are trading at approximately $418.93, reflecting a slight increase of 0.04%.
14:50 21.10.2024
UBS has maintained a "Buy" rating for Sanofi, setting a target price of 110 euros, following the announcement of the planned sale of a majority stake in its consumer division, Opella. Analyst Jo Walton expressed optimism about the increased clarity regarding the divestiture, which is expected to yield cash proceeds in the high single-digit billion range.
14:49 21.10.2024
UBS has reaffirmed its 'buy' recommendation on Microsoft, maintaining a price target of $510, which suggests a 22% upside potential. The firm believes that increased Azure revenues driven by OpenAI will outweigh any negative impact on earnings per share, and a relaxation of the exclusive computing agreement could benefit Microsoft.
14:48 21.10.2024
UBS has reaffirmed its 'buy' recommendation on Microsoft, maintaining a price target of $510, which suggests a 22% growth potential. The broker notes that increased Azure revenues from OpenAI are expected to outweigh any negative impact on earnings per share, and a relaxation of the exclusive computing agreement could benefit Microsoft.
14:48 21.10.2024
Bpifrance has acquired a 2% stake in Opella, a Sanofi subsidiary, for between 100 and 150 million euros, aiming to maintain influence despite lacking blocking power on the Board of Directors. The French government has secured guarantees for the preservation of production sites and R&D in France amid concerns over nationalization proposals. Bpifrance"s CEO argues against nationalization, warning it could lead to broader implications for the French chemical industry.
UBS has sold its 50% stake in Swisscard to American Express, which now becomes the sole owner of the credit card specialist. This decision aligns with UBS's strategic priorities, as Swisscard will continue to issue cards under American Express, Mastercard, and Visa licenses, while Credit Suisse customers will transition to UBS's credit card platform.
14:45 21.10.2024
UBS maintains a "Buy" rating on Microsoft, according to an analysis published by Cercle Finance. BOURSORAMA, acting solely as a distribution channel, emphasizes that the information is provided "as is" without any warranties, and the opinions expressed do not reflect its views. The institution adheres to strict conflict of interest management policies to ensure objectivity in its investment recommendations.
14:43 21.10.2024
The global medical carts market is projected to reach $4,844.3 million by 2032, growing at a CAGR of 11.24% from $1,857.3 million in 2023, driven by rising healthcare demands and technological advancements. Procedure carts are gaining traction, expected to capture over 25% market share, reflecting the increasing complexity of medical procedures and the need for efficient healthcare logistics. Despite high costs and maintenance challenges, the integration of smart technology and IoT is transforming the sector, enhancing operational efficiency in hospitals and clinics worldwide.
US equities are at record highs as the presidential election approaches, with the S&P 500 experiencing its longest winning streak this year. Despite election-related volatility, strong earnings growth and economic momentum suggest that investors should remain invested rather than make drastic portfolio changes. The election outcome may take weeks to determine, and potential market reactions will depend on the actual implementation of policies by the winning candidate.
14:36 21.10.2024
Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings